Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
The prognostic value of FoxP3 + regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3 + Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL a...
Saved in:
Published in | Scientific reports Vol. 5; no. 1; p. 15179 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
14.10.2015
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
ISSN | 2045-2322 2045-2322 |
DOI | 10.1038/srep15179 |
Cover
Loading…
Abstract | The prognostic value of FoxP3
+
regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3
+
Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL and Scopus were searched to identify eligible studies. In total, we analyzed 76 articles encompassing 17 types of cancer and including 15,512 cancer cases. The overall pooled analysis including all types of cancer suggested FoxP3
+
Tregs had a significant negative effect on overall survival (OS) (OR 1.46, P < 0.001), but the prognostic effect varied greatly according to tumor site. High FoxP3
+
Tregs infiltration was significantly associated with shorter OS in the majority of solid tumors studied, including cervical, renal, melanomas and breast cancers,
et al
; whereas, FoxP3
+
Tregs were associated with improved survival in colorectal, head and neck and oesophageal cancers. The stratified analysis suggested the molecular subtype and tumor stage significantly influenced the prognostic value of FoxP3
+
Tregs in certain types of cancer. In conclusion, our meta-analysis suggests that the prognostic role of FoxP3
+
Tregs was highly influenced by tumor site and was also correlated with the molecular subtype and tumor stage. |
---|---|
AbstractList | The prognostic value of FoxP3
+
regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3
+
Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched to identify eligible studies. In total, we analyzed 76 articles encompassing 17 types of cancer, and including 15,512 cancer cases. The overall pooled analysis including all types of cancer suggested FoxP3
+
Tregs had a significant negative effect on overall survival (OS) (OR 1.46, P < 0.001), but the prognostic effect varied greatly according to tumor site. High FoxP3
+
Tregs infiltration was significantly associated with shorter OS in the majority of solid tumors studied, including cervical, renal, melanomas, and breast cancers,
et al
; whereas, FoxP3
+
Tregs were associated with improved survival in colorectal, head and neck, and oesophageal cancers. The stratified analysis suggested the molecular subtype and tumor stage significantly influenced the prognostic value of FoxP3
+
Tregs in certain types of cancer. In conclusion, our meta-analysis suggests that the prognostic role of FoxP3
+
Tregs was highly influenced by tumor site, and was also correlated with the molecular subtype and tumor stage. The prognostic value of FoxP3+ regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3+ Treg across different types of cancer and to investigate factors associated with variations in this effect. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched to identify eligible studies. In total, we analyzed 76 articles encompassing 17 types of cancer, and including 15,512 cancer cases. The overall pooled analysis including all types of cancer suggested FoxP3+ Tregs had a significant negative effect on overall survival (OS) (OR 1.46, P < 0.001), but the prognostic effect varied greatly according to tumor site. High FoxP3+ Tregs infiltration was significantly associated with shorter OS in the majority of solid tumors studied, including cervical, renal, melanomas, and breast cancers, et al; whereas, FoxP3+ Tregs were associated with improved survival in colorectal, head and neck, and oesophageal cancers. The stratified analysis suggested the molecular subtype and tumor stage significantly influenced the prognostic value of FoxP3+ Tregs in certain types of cancer. In conclusion, our meta-analysis suggests that the prognostic role of FoxP3+ Tregs was highly influenced by tumor site, and was also correlated with the molecular subtype and tumor stage. |
ArticleNumber | 15179 |
Author | Jiang, Shu-juan Liu, Yao Shang, Bin Liu, Yi |
Author_xml | – sequence: 1 givenname: Bin surname: Shang fullname: Shang, Bin organization: Department of thoracic surgery, Provincial Hospital Affiliated to Shandong University – sequence: 2 givenname: Yao surname: Liu fullname: Liu, Yao organization: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University – sequence: 3 givenname: Shu-juan surname: Jiang fullname: Jiang, Shu-juan organization: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University – sequence: 4 givenname: Yi surname: Liu fullname: Liu, Yi organization: Department of Respiratory Medicine, Provincial Hospital Affiliated to Shandong University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26462617$$D View this record in MEDLINE/PubMed |
BookMark | eNptkV9vFCEUxYmpsbX2wS9gSHzxT8YCwzDQBxPTWDVpYh_q8-QOCyPNDKzArO63l8nWzVrlBZL7uyfncJ6iIx-8Qeg5Je8oqeV5imZNG9qqR-iEEd5UrGbs6OB9jM5SuiPlNExxqp6gYya4YIK2JyjexDD4kLLTeAPjbHCwOM9TiJXz1o05QnZ-wFfh1039FkczzCPkELf4Fmszjgk7jzV4bWK6wIDTNmUzwSIXzcaZnxj8Ck8mQwUexm1y6Rl6bGFM5uz-PkXfrj7eXn6urr9--nL54brSvJa5Utb0K2uhASGUsBwktYqApkRJ2QJf2V5zU4umlw3tW61qMLJRjWINEb1i9Sl6v9Ndz_1kVtr4Embs1tFNELddANf9PfHuezeETccF4bxdBF7dC8TwYzYpd5NLS2jwJsypoy1jnJFayIK-fIDehTmWwIWSSrVScikK9eLQ0d7KnzoK8HoH6BhSKdbuEUq6pe1u33Zhzx-w2uXy8WEJ48b_brzZbaSi6gcTD0z-A_8G77q8tg |
CitedBy_id | crossref_primary_10_1007_s40259_018_0277_2 crossref_primary_10_1016_j_devcel_2023_05_010 crossref_primary_10_1016_j_molimm_2024_08_004 crossref_primary_10_1186_s12885_022_10239_6 crossref_primary_10_2478_prolas_2022_0033 crossref_primary_10_3390_cells11132050 crossref_primary_10_1158_1078_0432_CCR_21_2781 crossref_primary_10_1371_journal_pone_0305648 crossref_primary_10_1038_s41379_021_00868_w crossref_primary_10_1073_pnas_1820388116 crossref_primary_10_1080_2162402X_2017_1284720 crossref_primary_10_3389_fimmu_2021_770390 crossref_primary_10_3390_cells11101672 crossref_primary_10_1186_s40425_018_0418_7 crossref_primary_10_3389_fimmu_2019_01720 crossref_primary_10_3389_fimmu_2020_573920 crossref_primary_10_1016_j_immuni_2023_06_003 crossref_primary_10_17650_1726_9784_2021_20_3_25_33 crossref_primary_10_1007_s00403_024_03758_8 crossref_primary_10_1007_s13402_021_00587_z crossref_primary_10_1002_2211_5463_12878 crossref_primary_10_1038_s41598_021_98716_z crossref_primary_10_1126_sciadv_adr7934 crossref_primary_10_3389_fonc_2023_1119343 crossref_primary_10_3390_medicina59020205 crossref_primary_10_3390_ijms19020611 crossref_primary_10_1016_j_ajoms_2019_06_005 crossref_primary_10_1080_2162402X_2016_1186323 crossref_primary_10_1016_j_oooo_2020_02_010 crossref_primary_10_1038_nri_2017_142 crossref_primary_10_3390_cancers11091221 crossref_primary_10_3389_fimmu_2023_1225175 crossref_primary_10_3390_cancers11091223 crossref_primary_10_1136_jitc_2021_002792 crossref_primary_10_1111_his_13987 crossref_primary_10_4049_jimmunol_2200041 crossref_primary_10_18632_oncotarget_9130 crossref_primary_10_4236_ojog_2021_112017 crossref_primary_10_18632_oncotarget_11039 crossref_primary_10_1007_s10528_024_10667_y crossref_primary_10_1111_imm_12954 crossref_primary_10_1038_s41392_021_00658_5 crossref_primary_10_12677_hjbm_2024_144061 crossref_primary_10_1155_2018_9325261 crossref_primary_10_3390_life11121318 crossref_primary_10_3389_fimmu_2024_1415457 crossref_primary_10_18632_aging_204860 crossref_primary_10_3389_fimmu_2024_1379376 crossref_primary_10_1016_j_cytogfr_2017_04_001 crossref_primary_10_1002_mc_23196 crossref_primary_10_18027_2224_5057_2022_2_3s1_3_8 crossref_primary_10_3389_fimmu_2021_627932 crossref_primary_10_1515_hsz_2020_0326 crossref_primary_10_1016_j_critrevonc_2020_103041 crossref_primary_10_1038_cr_2016_151 crossref_primary_10_3389_fimmu_2019_00650 crossref_primary_10_1038_s41392_023_01471_y crossref_primary_10_1080_23808993_2019_1634471 crossref_primary_10_3389_fimmu_2019_00653 crossref_primary_10_1016_j_immuni_2017_08_014 crossref_primary_10_1038_s41416_021_01331_y crossref_primary_10_3389_fimmu_2024_1326753 crossref_primary_10_1007_s00432_022_04101_2 crossref_primary_10_1016_j_cellimm_2017_05_007 crossref_primary_10_1126_scitranslmed_abf8495 crossref_primary_10_3390_cancers13112638 crossref_primary_10_3390_cancers13020210 crossref_primary_10_1158_1078_0432_CCR_17_0162 crossref_primary_10_18632_oncotarget_17722 crossref_primary_10_1002_eji_201847659 crossref_primary_10_3390_ijms24097956 crossref_primary_10_1186_s13046_021_01983_x crossref_primary_10_1038_bjc_2017_269 crossref_primary_10_1038_s41551_022_00977_0 crossref_primary_10_3389_fonc_2020_00614 crossref_primary_10_1007_s12307_017_0198_5 crossref_primary_10_1038_s41416_021_01660_y crossref_primary_10_1158_0008_5472_CAN_18_3622 crossref_primary_10_1016_j_canlet_2020_12_021 crossref_primary_10_3389_fonc_2022_815223 crossref_primary_10_3389_fmolb_2021_717038 crossref_primary_10_1177_15330338211045820 crossref_primary_10_3390_cancers11020227 crossref_primary_10_1002_jcp_31327 crossref_primary_10_3390_cancers14071785 crossref_primary_10_3390_healthcare7030108 crossref_primary_10_1016_j_bbcan_2017_05_001 crossref_primary_10_3390_cells9061503 crossref_primary_10_1155_2022_8757656 crossref_primary_10_3389_fimmu_2018_02165 crossref_primary_10_1007_s00262_020_02722_5 crossref_primary_10_1111_cas_14135 crossref_primary_10_3390_biomedicines9060653 crossref_primary_10_3390_medicina55060307 crossref_primary_10_5021_ad_22_175 crossref_primary_10_1007_s00432_020_03398_1 crossref_primary_10_1128_spectrum_04596_22 crossref_primary_10_1097_MD_0000000000030192 crossref_primary_10_4103_tcmj_tcmj_162_20 crossref_primary_10_3389_fimmu_2017_01617 crossref_primary_10_1182_blood_2023022000 crossref_primary_10_1158_0008_5472_CAN_22_0654 crossref_primary_10_1136_jitc_2021_002865 crossref_primary_10_1158_2326_6066_CIR_23_0573 crossref_primary_10_1158_2326_6066_CIR_20_0034 crossref_primary_10_12677_acm_2024_1472004 crossref_primary_10_3389_fimmu_2022_793234 crossref_primary_10_1016_j_molimm_2021_02_014 crossref_primary_10_1038_s10038_018_0468_1 crossref_primary_10_1080_10408363_2019_1660303 crossref_primary_10_1080_2162402X_2016_1150398 crossref_primary_10_3389_fmed_2022_1026521 crossref_primary_10_1111_pin_13099 crossref_primary_10_1016_j_ejca_2023_05_019 crossref_primary_10_1111_cas_15136 crossref_primary_10_1016_j_ejca_2024_113535 crossref_primary_10_3390_cells9112364 crossref_primary_10_1002_JLB_5MR0717_275RR crossref_primary_10_1146_annurev_immunol_042718_041717 crossref_primary_10_1038_s41598_021_02449_y crossref_primary_10_1097_01_XEJ_0000534717_60403_bb crossref_primary_10_3389_fimmu_2023_1275890 crossref_primary_10_1016_j_intimp_2023_110038 crossref_primary_10_1111_jop_12927 crossref_primary_10_1002_cam4_4017 crossref_primary_10_1186_s12885_018_5117_8 crossref_primary_10_1016_j_cell_2019_02_005 crossref_primary_10_1016_j_genrep_2022_101694 crossref_primary_10_1136_jitc_2021_002873 crossref_primary_10_20517_cdr_2023_46 crossref_primary_10_20517_cdr_2023_47 crossref_primary_10_20538_1682_0363_2022_1_171_182 crossref_primary_10_1080_2162402X_2023_2247303 crossref_primary_10_3390_cancers16132296 crossref_primary_10_1007_s00262_020_02517_8 crossref_primary_10_1016_j_canlet_2018_07_024 crossref_primary_10_1038_nrd_2018_148 crossref_primary_10_1038_s41590_021_00930_4 crossref_primary_10_1093_immadv_ltaa001 crossref_primary_10_1158_1055_9965_EPI_20_0714 crossref_primary_10_1172_jci_insight_95692 crossref_primary_10_1097_MD_0000000000031382 crossref_primary_10_1038_s41467_021_21573_x crossref_primary_10_1007_s00262_020_02604_w crossref_primary_10_1002_jso_25091 crossref_primary_10_1038_s41698_024_00748_x crossref_primary_10_1186_s13000_019_0900_7 crossref_primary_10_1007_s00103_020_03230_8 crossref_primary_10_1136_jitc_2020_001355 crossref_primary_10_3389_fimmu_2020_01633 crossref_primary_10_1136_gutjnl_2018_316510 crossref_primary_10_3389_fimmu_2021_832942 crossref_primary_10_3389_fimmu_2024_1433299 crossref_primary_10_1038_s41368_022_00160_w crossref_primary_10_7554_eLife_69015 crossref_primary_10_1038_s41598_018_21861_5 crossref_primary_10_1152_physrev_00018_2019 crossref_primary_10_3389_fimmu_2021_783282 crossref_primary_10_1158_2326_6066_CIR_22_0699 crossref_primary_10_1111_sji_13322 crossref_primary_10_1016_j_ccell_2023_02_014 crossref_primary_10_1080_2162402X_2024_2320411 crossref_primary_10_1111_cei_13567 crossref_primary_10_3390_cancers11020140 crossref_primary_10_1186_s12917_019_2100_9 crossref_primary_10_1227_neu_0000000000002237 crossref_primary_10_2139_ssrn_3155506 crossref_primary_10_1016_j_jbior_2020_100722 crossref_primary_10_3389_fimmu_2024_1403771 crossref_primary_10_3390_ijms22020867 crossref_primary_10_1016_j_isci_2022_105529 crossref_primary_10_1016_j_canlet_2019_10_032 crossref_primary_10_1186_s40425_019_0690_1 crossref_primary_10_1016_j_euros_2020_06_003 crossref_primary_10_3389_fonc_2021_649710 crossref_primary_10_1371_journal_pone_0315284 crossref_primary_10_3390_cancers15041262 crossref_primary_10_1016_j_molimm_2019_11_008 crossref_primary_10_1136_jitc_2021_002383 crossref_primary_10_3390_biomedicines13010134 crossref_primary_10_1007_s11523_017_0547_9 crossref_primary_10_1080_07357907_2017_1309545 crossref_primary_10_3390_cancers14010205 crossref_primary_10_1093_narcan_zcad055 crossref_primary_10_3892_ol_2019_10896 crossref_primary_10_1002_eji_202250258 crossref_primary_10_1016_j_iotech_2019_05_001 crossref_primary_10_3389_fimmu_2022_903564 crossref_primary_10_3390_cancers11081128 crossref_primary_10_3390_vaccines10050740 crossref_primary_10_1155_2022_5851755 crossref_primary_10_3389_fimmu_2022_855849 crossref_primary_10_1016_j_immuni_2017_03_013 crossref_primary_10_1016_j_heliyon_2018_e00880 crossref_primary_10_1186_s12935_020_01517_z crossref_primary_10_1007_s00262_019_02327_7 crossref_primary_10_1016_j_ccell_2023_04_003 crossref_primary_10_3389_fonc_2020_01211 crossref_primary_10_1016_j_heliyon_2024_e26094 crossref_primary_10_1016_j_ymthe_2017_05_006 crossref_primary_10_1158_1055_9965_EPI_21_1334 crossref_primary_10_1158_0008_5472_CAN_20_1885 crossref_primary_10_3390_cells13121057 crossref_primary_10_1007_s00011_019_01215_1 crossref_primary_10_1186_s13018_024_04885_8 crossref_primary_10_1080_21645515_2022_2060019 crossref_primary_10_1016_j_jid_2019_03_1162 crossref_primary_10_1002_2056_4538_12386 crossref_primary_10_1080_1744666X_2023_2262140 crossref_primary_10_3389_fonc_2024_1442103 crossref_primary_10_1007_s00262_019_02349_1 crossref_primary_10_1155_2022_1094607 crossref_primary_10_3389_fimmu_2021_792691 crossref_primary_10_1016_j_jconrel_2022_06_024 crossref_primary_10_3389_fonc_2023_1182434 crossref_primary_10_1080_2162402X_2019_1593806 crossref_primary_10_1111_cup_14381 crossref_primary_10_3389_fmolb_2021_583028 crossref_primary_10_3390_cells11182826 crossref_primary_10_61186_ijbc_16_4_56 crossref_primary_10_1002_hed_26158 crossref_primary_10_3389_fimmu_2021_717421 crossref_primary_10_3390_cancers13225748 crossref_primary_10_1158_2326_6066_CIR_17_0466 crossref_primary_10_2147_IJGM_S439190 crossref_primary_10_1186_s40425_019_0708_8 crossref_primary_10_3390_cancers15061901 crossref_primary_10_1186_s12935_022_02626_7 crossref_primary_10_3390_cancers11091398 crossref_primary_10_3390_cancers12020284 crossref_primary_10_3390_vaccines12060633 crossref_primary_10_3390_cancers12020287 crossref_primary_10_3390_ijms22010190 crossref_primary_10_1016_j_arr_2025_102715 crossref_primary_10_1634_theoncologist_2019_0123 crossref_primary_10_3390_ijms23158707 crossref_primary_10_3390_biomedicines6010025 crossref_primary_10_3390_ijms241411673 crossref_primary_10_1016_j_intimp_2019_105965 crossref_primary_10_1159_000531024 crossref_primary_10_3390_vaccines8020259 crossref_primary_10_1007_s12672_023_00787_z crossref_primary_10_1158_1078_0432_CCR_20_0328 crossref_primary_10_1172_jci_insight_151035 crossref_primary_10_1021_acsptsci_4c00358 crossref_primary_10_1038_s41598_017_08128_1 crossref_primary_10_1186_s12967_022_03667_2 crossref_primary_10_1038_s41540_024_00387_9 crossref_primary_10_1007_s00432_023_05499_z crossref_primary_10_3389_fimmu_2022_1038927 crossref_primary_10_1038_s41467_019_09416_2 crossref_primary_10_1038_ncomms15365 crossref_primary_10_1242_dmm_036236 crossref_primary_10_1080_15384101_2022_2029996 crossref_primary_10_18632_oncotarget_17340 crossref_primary_10_1016_j_cps_2021_06_005 crossref_primary_10_1155_2022_4954457 crossref_primary_10_1016_j_semcancer_2021_03_036 crossref_primary_10_1016_j_compbiomed_2025_110021 crossref_primary_10_1080_10715762_2023_2193308 crossref_primary_10_1158_0008_5472_CAN_18_0365 crossref_primary_10_1016_j_ccell_2024_05_013 crossref_primary_10_1186_s12935_021_01766_6 crossref_primary_10_3390_cancers14092214 crossref_primary_10_1111_exd_14721 crossref_primary_10_3390_cancers14163862 crossref_primary_10_1371_journal_pone_0191065 crossref_primary_10_2139_ssrn_4170185 crossref_primary_10_3390_jcm11051432 crossref_primary_10_1007_s40944_023_00756_y crossref_primary_10_4049_jimmunol_1701703 crossref_primary_10_3389_fddev_2022_823412 crossref_primary_10_3390_cells12192404 crossref_primary_10_3390_ijms21093352 crossref_primary_10_1016_S1877_1203_22_00122_7 crossref_primary_10_1080_2162402X_2018_1442999 crossref_primary_10_1038_s41418_021_00892_y crossref_primary_10_1016_j_biomaterials_2019_04_024 crossref_primary_10_3389_fimmu_2022_866937 crossref_primary_10_1186_s12885_024_12603_0 crossref_primary_10_1155_2019_5981054 crossref_primary_10_3390_cancers15113046 crossref_primary_10_1177_1010428320971404 crossref_primary_10_1016_j_ygyno_2022_10_022 crossref_primary_10_3389_fcimb_2021_649815 crossref_primary_10_1016_j_bioorg_2022_106141 crossref_primary_10_14639_0392_100X_2481 crossref_primary_10_3390_vaccines8010111 crossref_primary_10_1172_jci_insight_154646 crossref_primary_10_3389_fimmu_2020_616949 crossref_primary_10_3389_fimmu_2023_1328651 crossref_primary_10_3390_cancers15092420 crossref_primary_10_1002_hed_27040 crossref_primary_10_1007_s00251_022_01291_4 crossref_primary_10_1007_s12253_019_00695_0 crossref_primary_10_3389_fimmu_2024_1355945 crossref_primary_10_1016_j_bcp_2021_114697 crossref_primary_10_3389_fonc_2019_00827 crossref_primary_10_1007_s00262_019_02317_9 crossref_primary_10_1007_s00262_018_2248_3 crossref_primary_10_1186_s12935_021_02024_5 crossref_primary_10_1136_jitc_2021_003892 crossref_primary_10_3389_fphar_2019_00200 crossref_primary_10_1158_1078_0432_CCR_19_1872 crossref_primary_10_18027_2224_5057_2024_029 crossref_primary_10_1093_oncolo_oyad199 crossref_primary_10_1016_j_coi_2024_102511 crossref_primary_10_3390_cancers12092692 crossref_primary_10_2482_haigan_64_310 crossref_primary_10_1007_s00262_020_02645_1 crossref_primary_10_3389_fonc_2021_684098 crossref_primary_10_1016_j_oraloncology_2019_104560 crossref_primary_10_1186_s12935_021_02378_w crossref_primary_10_3389_fimmu_2018_00232 crossref_primary_10_3892_ol_2018_9226 crossref_primary_10_1016_j_clon_2018_05_008 crossref_primary_10_1002_jcb_29613 crossref_primary_10_18632_oncotarget_11943 crossref_primary_10_3389_fimmu_2021_718621 crossref_primary_10_1007_s00441_016_2474_y crossref_primary_10_1080_1744666X_2024_2334258 crossref_primary_10_1002_ijc_32571 crossref_primary_10_1016_j_ejca_2016_03_085 crossref_primary_10_1080_01616412_2016_1188473 crossref_primary_10_3389_fimmu_2017_00341 crossref_primary_10_1002_adhm_202001415 crossref_primary_10_1007_s00262_020_02842_y crossref_primary_10_1016_j_labinv_2025_104094 crossref_primary_10_3390_cancers13235878 crossref_primary_10_1007_s00262_020_02657_x crossref_primary_10_3390_healthcare10020342 crossref_primary_10_1016_j_modpat_2023_100218 crossref_primary_10_1038_nrc_2017_86 crossref_primary_10_24060_2076_3093_2021_11_4_328_336 crossref_primary_10_1016_j_vetimm_2018_06_011 crossref_primary_10_3389_fphys_2017_00950 crossref_primary_10_1007_s00262_020_02633_5 crossref_primary_10_1016_j_meegid_2018_08_014 crossref_primary_10_3390_cancers13010048 crossref_primary_10_1146_annurev_med_060116_022926 crossref_primary_10_1136_jitc_2021_002339 crossref_primary_10_1080_15384047_2016_1235666 crossref_primary_10_1038_s12276_018_0130_1 crossref_primary_10_1073_pnas_1810580115 crossref_primary_10_1080_2162402X_2020_1841948 crossref_primary_10_1186_s12967_020_02336_6 crossref_primary_10_1007_s12029_020_00376_1 crossref_primary_10_3389_fmolb_2022_833771 crossref_primary_10_1007_s00432_021_03753_w crossref_primary_10_1016_j_oraloncology_2017_02_023 crossref_primary_10_3390_molecules23061308 crossref_primary_10_1186_s13040_024_00404_x crossref_primary_10_1038_s41576_024_00761_7 crossref_primary_10_1080_21645515_2021_1891817 crossref_primary_10_1002_eji_201948470 crossref_primary_10_1016_j_heliyon_2024_e34632 crossref_primary_10_3389_fimmu_2023_1337333 crossref_primary_10_1111_imm_13494 crossref_primary_10_1097_MD_0000000000026017 crossref_primary_10_1101_cshperspect_a037044 crossref_primary_10_3390_ijms22010450 crossref_primary_10_1016_j_jhep_2020_11_036 crossref_primary_10_1126_sciimmunol_adf6717 crossref_primary_10_1158_2767_9764_CRC_24_0257 crossref_primary_10_1038_s41416_020_0943_2 crossref_primary_10_1186_s12943_018_0913_y crossref_primary_10_1002_cac2_12546 crossref_primary_10_1007_s11255_020_02592_x crossref_primary_10_1016_j_jid_2018_06_178 crossref_primary_10_1038_s41598_024_80489_w crossref_primary_10_1155_2018_1812535 crossref_primary_10_3389_fonc_2023_1134063 crossref_primary_10_1007_s00262_021_03033_z crossref_primary_10_3390_cancers13071587 crossref_primary_10_1007_s10238_024_01362_8 crossref_primary_10_3390_cancers10020039 crossref_primary_10_1111_imm_13016 crossref_primary_10_1155_2018_9128754 crossref_primary_10_1080_2162402X_2017_1341030 crossref_primary_10_3389_fped_2020_00454 crossref_primary_10_1016_j_pathol_2016_10_005 crossref_primary_10_3390_cancers14225560 crossref_primary_10_1155_2022_4946197 crossref_primary_10_3390_ijms24021527 crossref_primary_10_1016_j_jare_2024_07_030 crossref_primary_10_1152_ajpcell_00189_2022 crossref_primary_10_1016_j_addr_2019_06_005 crossref_primary_10_3390_cancers12102870 crossref_primary_10_1007_s13273_019_0017_9 crossref_primary_10_3390_cancers12071826 crossref_primary_10_1080_2162402X_2020_1760067 crossref_primary_10_1021_acsnano_8b05893 crossref_primary_10_3389_fonc_2021_662010 crossref_primary_10_1016_j_lungcan_2018_10_021 crossref_primary_10_3389_fimmu_2021_662134 crossref_primary_10_1002_lary_29689 crossref_primary_10_3390_ijms25126377 crossref_primary_10_12677_acm_2025_151069 crossref_primary_10_1158_1535_7163_MCT_20_0464 crossref_primary_10_1016_j_ccell_2021_09_008 crossref_primary_10_1371_journal_pone_0252480 crossref_primary_10_1007_s00262_020_02686_6 crossref_primary_10_1146_annurev_immunol_070621_030155 crossref_primary_10_1007_s00262_020_02784_5 crossref_primary_10_1016_j_bcmd_2016_04_004 crossref_primary_10_1158_2326_6066_CIR_20_0637 crossref_primary_10_1080_03009734_2018_1555195 crossref_primary_10_1016_j_semcancer_2022_01_006 crossref_primary_10_4049_jimmunol_2001203 crossref_primary_10_5858_arpa_2021_0169_OA crossref_primary_10_1073_pnas_1815087116 crossref_primary_10_3390_ijms21249705 crossref_primary_10_1007_s11912_020_00938_3 crossref_primary_10_3390_cancers15092453 crossref_primary_10_3390_jcm9051383 crossref_primary_10_1038_s41598_018_28277_1 crossref_primary_10_1080_14712598_2021_1825679 crossref_primary_10_1016_j_nantod_2020_101045 crossref_primary_10_1002_wsbm_1539 crossref_primary_10_1016_j_trecan_2019_11_003 crossref_primary_10_1177_0300985818808530 crossref_primary_10_1016_j_mam_2020_100936 crossref_primary_10_1016_j_heliyon_2022_e10450 crossref_primary_10_1042_BCJ20210233 crossref_primary_10_1007_s13402_021_00601_4 crossref_primary_10_1038_s41598_022_27237_0 crossref_primary_10_1038_s43018_020_00155_8 crossref_primary_10_1158_1078_0432_CCR_18_1100 crossref_primary_10_1097_XCS_0000000000000440 crossref_primary_10_1186_s12935_022_02684_x crossref_primary_10_3389_fgene_2022_948734 crossref_primary_10_3389_fimmu_2021_723609 crossref_primary_10_1126_sciimmunol_abn6173 crossref_primary_10_1158_1078_0432_CCR_22_1843 crossref_primary_10_1038_s41467_017_02289_3 crossref_primary_10_1002_lary_28336 crossref_primary_10_1038_s41598_024_60049_y crossref_primary_10_1172_jci_insight_93652 crossref_primary_10_1016_j_canlet_2023_216441 crossref_primary_10_1016_j_semcancer_2019_01_006 crossref_primary_10_1136_jitc_2024_009662 crossref_primary_10_1016_j_molimm_2016_12_018 crossref_primary_10_3390_ijms22158030 crossref_primary_10_1186_s12885_023_10590_2 crossref_primary_10_3390_cancers14194887 crossref_primary_10_1016_j_heliyon_2025_e41736 crossref_primary_10_3390_vaccines4030028 crossref_primary_10_1186_s12967_023_03949_3 crossref_primary_10_18632_oncotarget_24835 crossref_primary_10_3389_fimmu_2022_968165 crossref_primary_10_3390_cancers14122876 crossref_primary_10_1186_s12943_019_0938_x crossref_primary_10_3390_cancers14122991 crossref_primary_10_3389_fimmu_2019_02453 crossref_primary_10_1002_hed_27671 crossref_primary_10_1016_j_imbio_2024_152822 crossref_primary_10_1186_s12967_020_02624_1 crossref_primary_10_3748_wjg_v24_i17_1839 crossref_primary_10_3389_fimmu_2018_00610 crossref_primary_10_1007_s00432_016_2223_3 crossref_primary_10_3389_fonc_2022_1021609 crossref_primary_10_3390_cancers15061642 crossref_primary_10_1080_21691401_2018_1482306 crossref_primary_10_3390_cells13050413 crossref_primary_10_1016_j_molimm_2016_12_001 crossref_primary_10_3390_ijms25137346 crossref_primary_10_1186_s41065_025_00381_z crossref_primary_10_1016_j_celrep_2018_10_047 crossref_primary_10_1136_jitc_2021_004378 crossref_primary_10_3389_fonc_2021_660039 crossref_primary_10_1111_1759_7714_15493 crossref_primary_10_1038_s41590_019_0429_7 crossref_primary_10_1016_j_trecan_2017_06_005 crossref_primary_10_1016_j_celrep_2017_06_062 crossref_primary_10_1016_j_ejca_2018_06_023 crossref_primary_10_1080_2162402X_2023_2192100 crossref_primary_10_1038_s41525_018_0054_7 crossref_primary_10_3390_cancers16234011 crossref_primary_10_1155_2020_2134647 crossref_primary_10_1111_imm_13562 crossref_primary_10_1016_j_omtn_2021_05_005 crossref_primary_10_3389_fonc_2024_1325575 crossref_primary_10_1186_s12967_022_03736_6 crossref_primary_10_3390_cancers13061440 crossref_primary_10_3390_cells10123309 crossref_primary_10_1038_s41598_019_40487_9 crossref_primary_10_3390_cells11223600 crossref_primary_10_1007_s00795_023_00367_8 crossref_primary_10_1186_s12967_023_04686_3 crossref_primary_10_3390_cancers14225539 crossref_primary_10_1002_anbr_202100006 crossref_primary_10_1007_s00262_023_03517_0 crossref_primary_10_3389_fimmu_2022_981479 crossref_primary_10_1007_s00292_018_0541_8 crossref_primary_10_1016_j_molimm_2023_04_005 crossref_primary_10_3389_fimmu_2023_1267279 crossref_primary_10_1097_MD_0000000000039998 crossref_primary_10_1152_physiol_00020_2022 crossref_primary_10_1007_s10528_022_10317_1 crossref_primary_10_1002_jev2_12390 crossref_primary_10_3390_v14050986 crossref_primary_10_1016_j_clgc_2024_01_008 crossref_primary_10_1186_s12885_019_5745_7 crossref_primary_10_1097_ot9_0000000000000041 crossref_primary_10_1172_jci_insight_161438 crossref_primary_10_1016_j_immuni_2023_09_004 crossref_primary_10_3390_biology10080808 crossref_primary_10_1016_j_celrep_2019_10_120 crossref_primary_10_2147_CMAR_S285128 crossref_primary_10_18632_oncotarget_21331 crossref_primary_10_3390_ijms24119279 crossref_primary_10_1002_cti2_1165 crossref_primary_10_3802_jgo_2023_34_e16 crossref_primary_10_1186_s12957_019_1621_9 crossref_primary_10_1016_j_omto_2023_01_001 crossref_primary_10_1111_imr_13287 crossref_primary_10_3389_fonc_2020_570819 crossref_primary_10_1002_eji_201847597 crossref_primary_10_1042_CS20210042 crossref_primary_10_1186_s12979_020_0174_7 crossref_primary_10_4049_jimmunol_1701188 crossref_primary_10_3390_cells10010045 crossref_primary_10_1172_JCI159283 crossref_primary_10_1097_SLA_0000000000002754 crossref_primary_10_1007_s00262_016_1902_x crossref_primary_10_1016_j_labinv_2024_102126 crossref_primary_10_3389_fimmu_2019_00911 crossref_primary_10_1016_j_tranon_2018_03_007 crossref_primary_10_1158_0008_5472_CAN_23_0613 crossref_primary_10_1007_s00262_021_02881_z crossref_primary_10_3389_fimmu_2022_994019 crossref_primary_10_3390_biomedicines11010189 crossref_primary_10_1038_s41598_025_85444_x crossref_primary_10_2147_JIR_S303750 crossref_primary_10_1080_15440478_2021_1993407 crossref_primary_10_1007_s00432_018_2602_z crossref_primary_10_1038_s41598_020_60255_4 crossref_primary_10_1016_j_xinn_2021_100194 crossref_primary_10_1080_2162402X_2017_1356148 crossref_primary_10_1016_j_immuni_2016_10_032 crossref_primary_10_18632_oncotarget_24504 crossref_primary_10_1016_j_canlet_2017_10_014 crossref_primary_10_1016_j_tranon_2022_101469 crossref_primary_10_3389_fgene_2023_1265866 crossref_primary_10_3390_cancers10090302 crossref_primary_10_1073_pnas_1812186116 crossref_primary_10_1080_2162402X_2018_1426519 crossref_primary_10_1038_s41379_022_01086_8 crossref_primary_10_1111_cei_13060 crossref_primary_10_18632_aging_202842 crossref_primary_10_1007_s00262_018_2288_8 crossref_primary_10_1136_jclinpath_2016_203978 crossref_primary_10_3389_fonc_2021_663749 crossref_primary_10_1016_j_adro_2018_08_018 crossref_primary_10_1007_s11427_018_9428_9 crossref_primary_10_2147_JIR_S441981 crossref_primary_10_1002_cam4_7059 crossref_primary_10_1002_eji_202350448 crossref_primary_10_1007_s00106_019_00758_3 crossref_primary_10_1002_eji_202451225 crossref_primary_10_3389_fimmu_2022_1001161 crossref_primary_10_1080_2162402X_2023_2175517 crossref_primary_10_1177_10732748211004878 crossref_primary_10_1186_s13014_021_01868_5 crossref_primary_10_2147_BCTT_S470570 crossref_primary_10_2147_JIR_S249384 crossref_primary_10_1016_j_cpt_2022_11_001 crossref_primary_10_1155_2021_8865791 crossref_primary_10_3389_fimmu_2022_1069192 crossref_primary_10_3390_cancers14092071 crossref_primary_10_3390_vaccines13020117 crossref_primary_10_3389_fmed_2022_834725 crossref_primary_10_1016_j_intimp_2023_110015 crossref_primary_10_1038_s41420_023_01765_8 crossref_primary_10_1186_s13046_023_02805_y crossref_primary_10_1093_annonc_mdx238 crossref_primary_10_3389_fimmu_2023_1259562 crossref_primary_10_1002_cam4_2611 crossref_primary_10_1016_j_euf_2021_04_014 crossref_primary_10_1016_j_cllc_2023_06_013 crossref_primary_10_3389_fphys_2020_511071 crossref_primary_10_3389_fonc_2023_1201497 crossref_primary_10_37349_emed_2023_00197 crossref_primary_10_1080_2162402X_2017_1338236 crossref_primary_10_1111_imm_12779 crossref_primary_10_3390_cancers14061580 crossref_primary_10_1007_s11684_018_0663_7 crossref_primary_10_3389_fonc_2022_1008714 crossref_primary_10_1016_j_jncc_2022_10_002 crossref_primary_10_3389_fcell_2021_725473 crossref_primary_10_1007_s00432_023_04916_7 crossref_primary_10_3389_fonc_2024_1346793 crossref_primary_10_1158_1940_6207_CAPR_22_0193 crossref_primary_10_1002_ijc_34281 crossref_primary_10_1007_s40259_020_00449_4 crossref_primary_10_1038_s41422_020_0337_2 crossref_primary_10_1080_02648725_2023_2166706 crossref_primary_10_3389_fonc_2021_625207 crossref_primary_10_3389_fcell_2021_726205 crossref_primary_10_3390_ijms20235822 crossref_primary_10_4049_jimmunol_1701021 crossref_primary_10_3390_ijms22084049 crossref_primary_10_1007_s00428_019_02565_1 crossref_primary_10_2147_OTT_S264312 crossref_primary_10_3389_fimmu_2022_892543 crossref_primary_10_1002_btm2_10314 crossref_primary_10_1016_j_jid_2020_10_011 crossref_primary_10_1177_0300985820960131 crossref_primary_10_1016_j_oraloncology_2020_105084 crossref_primary_10_3390_cancers13051018 crossref_primary_10_1002_jmv_25312 crossref_primary_10_1155_2017_5458178 crossref_primary_10_1186_s13058_019_1176_2 crossref_primary_10_3389_fimmu_2024_1501885 crossref_primary_10_3390_cancers15215232 crossref_primary_10_1007_s00262_017_2040_9 crossref_primary_10_1080_2162402X_2017_1288331 crossref_primary_10_3390_ijms23052496 crossref_primary_10_3389_fimmu_2017_01900 crossref_primary_10_2174_1381612826666200713171137 crossref_primary_10_1038_s41416_022_01875_7 crossref_primary_10_3389_fimmu_2019_01078 crossref_primary_10_1002_cam4_7368 crossref_primary_10_1016_j_humpath_2017_12_022 crossref_primary_10_1126_sciimmunol_abn0175 crossref_primary_10_1186_s40364_020_00257_6 crossref_primary_10_2147_CMAR_S265828 crossref_primary_10_1001_jamaoncol_2017_3684 crossref_primary_10_1186_s13045_018_0629_x crossref_primary_10_1007_s00795_021_00290_w crossref_primary_10_3857_roj_2021_00472 crossref_primary_10_1080_2162402X_2018_1537693 crossref_primary_10_1016_j_pathol_2021_10_002 crossref_primary_10_1158_2767_9764_CRC_24_0638 crossref_primary_10_1007_s12254_016_0270_8 crossref_primary_10_3389_fimmu_2022_835690 crossref_primary_10_1016_j_canlet_2020_07_022 crossref_primary_10_3390_cells13110941 crossref_primary_10_1155_2022_9593039 crossref_primary_10_3390_ijms25074134 crossref_primary_10_3390_ijms25126501 crossref_primary_10_1016_j_arabjc_2021_103121 crossref_primary_10_1007_s13402_024_00992_0 crossref_primary_10_18632_aging_102499 crossref_primary_10_1007_s00262_020_02694_6 crossref_primary_10_1016_j_bbmt_2017_11_012 crossref_primary_10_1136_jitc_2020_001749 crossref_primary_10_1016_j_prp_2021_153703 crossref_primary_10_1186_s12885_024_12851_0 crossref_primary_10_1016_j_canlet_2024_217086 crossref_primary_10_1002_cam4_5194 crossref_primary_10_1080_2162402X_2019_1614858 crossref_primary_10_3390_diagnostics12122987 crossref_primary_10_1002_jcp_29842 crossref_primary_10_2174_1386207325666220324092231 crossref_primary_10_1016_j_neo_2024_101091 crossref_primary_10_18632_oncotarget_26748 crossref_primary_10_1016_j_ctrv_2022_102499 crossref_primary_10_2147_CMAR_S460315 crossref_primary_10_1007_s13770_023_00585_2 crossref_primary_10_17650_2222_1468_2022_12_3_114_126 crossref_primary_10_1182_bloodadvances_2023010158 crossref_primary_10_1080_2162402X_2019_1644108 crossref_primary_10_1136_gutjnl_2016_311421 crossref_primary_10_3389_fonc_2021_739182 crossref_primary_10_3390_biomedicines10112732 crossref_primary_10_1371_journal_pone_0307038 crossref_primary_10_3390_biom12010132 crossref_primary_10_1038_s41467_021_26091_4 crossref_primary_10_1186_s12935_020_1104_7 crossref_primary_10_1016_j_crimmu_2023_100074 crossref_primary_10_1136_bmjopen_2021_060659 crossref_primary_10_3390_pharmaceutics14091768 crossref_primary_10_1007_s10120_019_00974_4 crossref_primary_10_1093_discim_kyae006 crossref_primary_10_1080_21645515_2018_1434384 crossref_primary_10_1007_s00432_023_05187_y crossref_primary_10_1038_s41598_022_23016_z crossref_primary_10_1111_cei_13044 crossref_primary_10_1016_j_xcrm_2021_100399 |
Cites_doi | 10.1002/sim.1186 10.1016/j.ejca.2008.05.017 10.1002/cncr.24317 10.1038/nm1093 10.1186/1745-6215-8-16 10.1182/blood-2006-04-018218 10.1158/0008-5472.CAN-04-3104 10.1038/cmi.2010.56 10.1007/s12253-010-9254-x 10.1038/sj.bjc.6602201 10.1007/s00432-010-0816-9 10.1200/JCO.2008.18.7229 10.1002/eji.200324181 10.1007/s10585-013-9602-9 10.1097/COC.0b013e318187dd40 10.1007/0-387-26283-0_3 10.1186/bcr2869 10.1002/cncr.22282 10.1158/1078-0432.CCR-11-3216 10.1371/journal.pmed.1000097 10.1126/science.1079490 10.1158/1078-0432.CCR-06-2139 10.1038/bjc.2012.524 10.1126/science.1129139 10.1158/1078-0432.CCR-04-1869 10.1200/JCO.2006.05.9584 10.1007/s00262-012-1277-6 10.4049/jimmunol.177.9.6540 10.1016/j.cell.2008.05.009 10.1002/cncr.25293 10.1073/pnas.0509182102 10.1158/0008-5472.CAN-07-6842 10.1158/0008-5472.CAN-10-1736 10.1111/j.1464-410X.2008.08151.x 10.1007/s00262-008-0583-5 10.1371/journal.pone.0042274 10.1111/bjd.12641 10.1158/1078-0432.CCR-07-4554 10.1200/JCO.2006.09.4565 10.1002/cncr.23712 10.1371/journal.pone.0006412 10.1158/1078-0432.CCR-05-1886 10.1053/j.gastro.2009.06.053 10.1002/ijc.24989 10.1002/cncr.24999 |
ContentType | Journal Article |
Copyright | The Author(s) 2015 Copyright Nature Publishing Group Oct 2015 Copyright © 2015, Macmillan Publishers Limited 2015 Macmillan Publishers Limited |
Copyright_xml | – notice: The Author(s) 2015 – notice: Copyright Nature Publishing Group Oct 2015 – notice: Copyright © 2015, Macmillan Publishers Limited 2015 Macmillan Publishers Limited |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
DOI | 10.1038/srep15179 |
DatabaseName | Springer Nature OA Free Journals (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database (ProQuest) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
EndPage | 15179 |
ExternalDocumentID | PMC4604472 26462617 10_1038_srep15179 |
Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS EJD ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7XB 8FK AARCD K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c438t-9febdffa5a6696f4a81f90ac109887a4dfbc4e365b851b7c93ae859592506b923 |
IEDL.DBID | M48 |
ISSN | 2045-2322 |
IngestDate | Thu Aug 21 14:12:11 EDT 2025 Fri Jul 11 15:38:42 EDT 2025 Wed Aug 13 06:31:34 EDT 2025 Mon Jul 21 06:08:24 EDT 2025 Tue Jul 01 03:15:09 EDT 2025 Thu Apr 24 23:00:46 EDT 2025 Fri Feb 21 02:39:35 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c438t-9febdffa5a6696f4a81f90ac109887a4dfbc4e365b851b7c93ae859592506b923 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-1 ObjectType-Article-3 ObjectType-Undefined-4 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/srep15179 |
PMID | 26462617 |
PQID | 1899788486 |
PQPubID | 2041939 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4604472 proquest_miscellaneous_1722420368 proquest_journals_1899788486 pubmed_primary_26462617 crossref_primary_10_1038_srep15179 crossref_citationtrail_10_1038_srep15179 springer_journals_10_1038_srep15179 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-10-14 |
PublicationDateYYYYMMDD | 2015-10-14 |
PublicationDate_xml | – month: 10 year: 2015 text: 2015-10-14 day: 14 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Scientific reports |
PublicationTitleAbbrev | Sci Rep |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2015 |
Publisher | Nature Publishing Group UK Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
References | Sato (CR3) 2005; 102 Curiel (CR13) 2004; 10 Chiba (CR7) 2004; 91 Galon (CR1) 2006; 313 West (CR31) 2013; 108 Klages (CR44) 2010; 70 Venet (CR39) 2006; 177 Salama (CR19) 2009; 27 Alvaro (CR34) 2005; 11 Ghiringhelli (CR42) 2004; 34 Demir (CR30) 2013; 30 Peng (CR9) 2012; 61 Gerber (CR25) 2014; 170 Shen (CR4) 2010; 136 Yoon (CR8) 2012; 7 Gao (CR14) 2007; 25 Badoual (CR36) 2008; 68 Higgins, Thompson (CR22) 2002; 21 Shah (CR17) 2011; 8 Milne (CR41) 2009; 4 Gerena-Lewis (CR43) 2009; 32 Moher, Liberati, Tetzlaff, Altman (CR20) 2009; 6 Li (CR24) 2009; 103 Miracco (CR28) 2007; 18 Jordanova (CR45) 2008; 14 Badoual (CR18) 2006; 12 Leffers (CR2) 2009; 58 Bates (CR12) 2006; 24 Carreras (CR35) 2006; 108 Yan (CR29) 2011; 13 deLeeuw, Kost, Kakal, Nelson (CR5) 2012; 18 Hori, Nomura, Sakaguchi (CR10) 2003; 299 Petersen (CR15) 2006; 107 Kawai (CR6) 2008; 113 Mougiakakos (CR26) 2010; 116 Sinicrope (CR46) 2009; 137 Frey (CR32) 2010; 126 Perrone (CR16) 2008; 44 Tierney, Stewart, Ghersi, Burdett, Sydes (CR21) 2007; 8 Erdman (CR38) 2005; 65 Lee, Park, Lee, Yun, Chun (CR33) 2010; 116 Ladanyi (CR27) 2010; 16 Sakaguchi, Yamaguchi, Nomura, Ono (CR11) 2008; 133 Schottelius, Dinter (CR37) 2006; 130 Adams (CR40) 2009; 115 Siddiqui (CR23) 2007; 13 T Chiba (BFsrep15179_CR7) 2004; 91 D Mougiakakos (BFsrep15179_CR26) 2010; 116 T Alvaro (BFsrep15179_CR34) 2005; 11 K1 Klages (BFsrep15179_CR44) 2010; 70 DM Frey (BFsrep15179_CR32) 2010; 126 S Hori (BFsrep15179_CR10) 2003; 299 F Ghiringhelli (BFsrep15179_CR42) 2004; 34 JP Higgins (BFsrep15179_CR22) 2002; 21 JF Tierney (BFsrep15179_CR21) 2007; 8 L Demir (BFsrep15179_CR30) 2013; 30 J Galon (BFsrep15179_CR1) 2006; 313 W Shah (BFsrep15179_CR17) 2011; 8 NR West (BFsrep15179_CR31) 2013; 108 C Badoual (BFsrep15179_CR36) 2008; 68 E Sato (BFsrep15179_CR3) 2005; 102 JF Li (BFsrep15179_CR24) 2009; 103 K Milne (BFsrep15179_CR41) 2009; 4 O Kawai (BFsrep15179_CR6) 2008; 113 C Badoual (BFsrep15179_CR18) 2006; 12 HH Yoon (BFsrep15179_CR8) 2012; 7 D Moher (BFsrep15179_CR20) 2009; 6 SF Adams (BFsrep15179_CR40) 2009; 115 ES Jordanova (BFsrep15179_CR45) 2008; 14 M Gerena-Lewis (BFsrep15179_CR43) 2009; 32 LS Peng (BFsrep15179_CR9) 2012; 61 M Yan (BFsrep15179_CR29) 2011; 13 S Sakaguchi (BFsrep15179_CR11) 2008; 133 A Ladanyi (BFsrep15179_CR27) 2010; 16 FA Sinicrope (BFsrep15179_CR46) 2009; 137 RJ deLeeuw (BFsrep15179_CR5) 2012; 18 SE Erdman (BFsrep15179_CR38) 2005; 65 Z Shen (BFsrep15179_CR4) 2010; 136 C Miracco (BFsrep15179_CR28) 2007; 18 J Carreras (BFsrep15179_CR35) 2006; 108 TJ Curiel (BFsrep15179_CR13) 2004; 10 P Salama (BFsrep15179_CR19) 2009; 27 N Leffers (BFsrep15179_CR2) 2009; 58 AL Gerber (BFsrep15179_CR25) 2014; 170 RP Petersen (BFsrep15179_CR15) 2006; 107 Q Gao (BFsrep15179_CR14) 2007; 25 SA Siddiqui (BFsrep15179_CR23) 2007; 13 AJ Schottelius (BFsrep15179_CR37) 2006; 130 G Perrone (BFsrep15179_CR16) 2008; 44 WS Lee (BFsrep15179_CR33) 2010; 116 GJ Bates (BFsrep15179_CR12) 2006; 24 F Venet (BFsrep15179_CR39) 2006; 177 |
References_xml | – volume: 21 start-page: 1539 year: 2002 end-page: 1558 ident: CR22 article-title: Quantifying heterogeneity in a meta-analysis publication-title: Stat Med doi: 10.1002/sim.1186 – volume: 44 start-page: 1875 year: 2008 end-page: 1882 ident: CR16 article-title: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.05.017 – volume: 115 start-page: 2891 year: 2009 end-page: 2902 ident: CR40 article-title: Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer publication-title: Cancer doi: 10.1002/cncr.24317 – volume: 10 start-page: 942 year: 2004 end-page: 949 ident: CR13 article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival publication-title: Nat Med doi: 10.1038/nm1093 – volume: 8 start-page: 16 year: 2007 ident: CR21 article-title: Practical methods for incorporating summary time-to-event data into meta-analysis publication-title: Trials doi: 10.1186/1745-6215-8-16 – volume: 108 start-page: 2957 year: 2006 end-page: 2964 ident: CR35 article-title: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma publication-title: Blood doi: 10.1182/blood-2006-04-018218 – volume: 65 start-page: 3998 year: 2005 end-page: 4004 ident: CR38 article-title: CD4 CD25 regulatory lymphocytes induce regression of intestinal tumors in ApcMin/ mice publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-3104 – volume: 8 start-page: 59 year: 2011 end-page: 66 ident: CR17 article-title: A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4( )FOXP3( ) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix publication-title: Cell Mol Immunol doi: 10.1038/cmi.2010.56 – volume: 16 start-page: 303 year: 2010 end-page: 309 ident: CR27 article-title: FOXP3 cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma publication-title: Pathol Oncol Res doi: 10.1007/s12253-010-9254-x – volume: 91 start-page: 1711 year: 2004 end-page: 1717 ident: CR7 article-title: Intraepithelial CD8 T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602201 – volume: 136 start-page: 1585 year: 2010 end-page: 1595 ident: CR4 article-title: Higher intratumoral infiltrated Foxp3 Treg numbers and Foxp3 /CD8 ratio are associated with adverse prognosis in resectable gastric cancer publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-010-0816-9 – volume: 27 start-page: 186 year: 2009 end-page: 192 ident: CR19 article-title: Tumor-infiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.7229 – volume: 34 start-page: 336 year: 2004 end-page: 344 ident: CR42 article-title: CD4 CD25 regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative publication-title: Eur J Immunol doi: 10.1002/eji.200324181 – volume: 30 start-page: 1047 year: 2013 end-page: 1062 ident: CR30 article-title: Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3 Tregs publication-title: Clin Exp Metastasis doi: 10.1007/s10585-013-9602-9 – volume: 32 start-page: 269 year: 2009 end-page: 273 ident: CR43 article-title: A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer publication-title: Am J Clin Oncol doi: 10.1097/COC.0b013e318187dd40 – volume: 130 start-page: 67 year: 2006 end-page: 87 ident: CR37 article-title: Cytokines, NF-kappaB, microenvironment, intestinal inflammation and cancer publication-title: Cancer Treat Res doi: 10.1007/0-387-26283-0_3 – volume: 13 start-page: R47 year: 2011 ident: CR29 article-title: Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression and is associated with poor prognosis in basal-like breast cancers publication-title: Breast Cancer Res doi: 10.1186/bcr2869 – volume: 107 start-page: 2866 year: 2006 end-page: 2872 ident: CR15 article-title: Tumor infiltrating Foxp3 regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients publication-title: Cancer doi: 10.1002/cncr.22282 – volume: 18 start-page: 3022 year: 2012 end-page: 3029 ident: CR5 article-title: The prognostic value of FoxP3 tumor-infiltrating lymphocytes in cancer: a critical review of the literature publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-3216 – volume: 6 start-page: e1000097 year: 2009 ident: CR20 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 299 start-page: 1057 year: 2003 end-page: 1061 ident: CR10 article-title: Control of regulatory T cell development by the transcription factor Foxp3 publication-title: Science doi: 10.1126/science.1079490 – volume: 13 start-page: 2075 year: 2007 end-page: 2081 ident: CR23 article-title: Tumor-infiltrating Foxp3-CD4 CD25 T cells predict poor survival in renal cell carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2139 – volume: 108 start-page: 155 year: 2013 end-page: 162 ident: CR31 article-title: Tumour-infiltrating FOXP3( ) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer publication-title: Br J Cancer doi: 10.1038/bjc.2012.524 – volume: 313 start-page: 1960 year: 2006 end-page: 1964 ident: CR1 article-title: Type, density and location of immune cells within human colorectal tumors predict clinical outcome publication-title: Science. doi: 10.1126/science.1129139 – volume: 11 start-page: 1467 year: 2005 end-page: 1473 ident: CR34 article-title: Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1869 – volume: 24 start-page: 5373 year: 2006 end-page: 5380 ident: CR12 article-title: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.9584 – volume: 18 start-page: 1115 year: 2007 end-page: 1122 ident: CR28 article-title: Utility of tumour-infiltrating CD25 FOXP3 regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma publication-title: Oncol Rep – volume: 61 start-page: 2183 year: 2012 end-page: 2192 ident: CR9 article-title: Increased tumor-infiltrating CD8( )Foxp3( ) T lymphocytes are associated with tumor progression in human gastric cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-012-1277-6 – volume: 116 start-page: 2224 year: 2010 end-page: 2233 ident: CR26 article-title: Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma publication-title: Cancer – volume: 177 start-page: 6540 year: 2006 end-page: 6547 ident: CR39 article-title: Human CD4 CD25 regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism publication-title: J Immunol doi: 10.4049/jimmunol.177.9.6540 – volume: 133 start-page: 775 year: 2008 end-page: 787 ident: CR11 article-title: Regulatory T cells and immune tolerance publication-title: Cell doi: 10.1016/j.cell.2008.05.009 – volume: 116 start-page: 5188 year: 2010 end-page: 5199 ident: CR33 article-title: Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer publication-title: Cancer doi: 10.1002/cncr.25293 – volume: 102 start-page: 18538 year: 2005 end-page: 18543 ident: CR3 article-title: Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8 /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0509182102 – volume: 68 start-page: 3907 year: 2008 end-page: 3914 ident: CR36 article-title: The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6842 – volume: 70 start-page: 7788 year: 2010 end-page: 99 ident: CR44 article-title: Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-1736 – volume: 103 start-page: 399 year: 2009 end-page: 405 ident: CR24 article-title: The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma publication-title: BJU Int doi: 10.1111/j.1464-410X.2008.08151.x – volume: 58 start-page: 449 year: 2009 end-page: 459 ident: CR2 article-title: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic le.sions of advanced stage ovarian cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0583-5 – volume: 7 start-page: e42274 year: 2012 ident: CR8 article-title: Prognostic impact of FoxP3 regulatory T cells in relation to CD8 T lymphocyte density in human colon carcinomas publication-title: PLoS One doi: 10.1371/journal.pone.0042274 – volume: 170 start-page: 103 year: 2014 end-page: 109 ident: CR25 article-title: High expression of FOXP3 in primary melanoma is associated with tumour progression publication-title: Br J Dermatol doi: 10.1111/bjd.12641 – volume: 14 start-page: 2028 year: 2008 end-page: 2035 ident: CR45 article-title: Human leukocyte antigen class I, MHC class I chain-related molecule A and CD8 /regulatory T-cell ratio: which variable determines survival of cervical cancer patients? publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4554 – volume: 126 start-page: 2635 year: 2010 end-page: 2643 ident: CR32 article-title: High frequency of tumor-infiltrating FOXP3( ) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients publication-title: Int J Cancer – volume: 25 start-page: 2586 year: 2007 end-page: 2593 ident: CR14 article-title: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.4565 – volume: 113 start-page: 1387 year: 2008 end-page: 1395 ident: CR6 article-title: Predominant infiltration of macrophages and CD8( ) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer publication-title: Cancer doi: 10.1002/cncr.23712 – volume: 4 start-page: e6412 year: 2009 ident: CR41 article-title: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors publication-title: PLoS One doi: 10.1371/journal.pone.0006412 – volume: 12 start-page: 465 year: 2006 end-page: 472 ident: CR18 article-title: Prognostic value of tumor-infiltrating CD4 T-cell subpopulations in head and neck cancers publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1886 – volume: 137 start-page: 1270 year: 2009 end-page: 1279 ident: CR46 article-title: Intraepithelial effector (CD3 )/regulatory (FoxP3 ) T-cell ratio predicts a clinical outcome of human colon carcinoma publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.06.053 – volume: 44 start-page: 1875 year: 2008 ident: BFsrep15179_CR16 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.05.017 – volume: 11 start-page: 1467 year: 2005 ident: BFsrep15179_CR34 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1869 – volume: 16 start-page: 303 year: 2010 ident: BFsrep15179_CR27 publication-title: Pathol Oncol Res doi: 10.1007/s12253-010-9254-x – volume: 12 start-page: 465 year: 2006 ident: BFsrep15179_CR18 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1886 – volume: 177 start-page: 6540 year: 2006 ident: BFsrep15179_CR39 publication-title: J Immunol doi: 10.4049/jimmunol.177.9.6540 – volume: 170 start-page: 103 year: 2014 ident: BFsrep15179_CR25 publication-title: Br J Dermatol doi: 10.1111/bjd.12641 – volume: 113 start-page: 1387 year: 2008 ident: BFsrep15179_CR6 publication-title: Cancer doi: 10.1002/cncr.23712 – volume: 4 start-page: e6412 year: 2009 ident: BFsrep15179_CR41 publication-title: PLoS One doi: 10.1371/journal.pone.0006412 – volume: 21 start-page: 1539 year: 2002 ident: BFsrep15179_CR22 publication-title: Stat Med doi: 10.1002/sim.1186 – volume: 58 start-page: 449 year: 2009 ident: BFsrep15179_CR2 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-008-0583-5 – volume: 116 start-page: 5188 year: 2010 ident: BFsrep15179_CR33 publication-title: Cancer doi: 10.1002/cncr.25293 – volume: 70 start-page: 7788 year: 2010 ident: BFsrep15179_CR44 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-1736 – volume: 34 start-page: 336 year: 2004 ident: BFsrep15179_CR42 publication-title: Eur J Immunol doi: 10.1002/eji.200324181 – volume: 8 start-page: 16 year: 2007 ident: BFsrep15179_CR21 publication-title: Trials doi: 10.1186/1745-6215-8-16 – volume: 65 start-page: 3998 year: 2005 ident: BFsrep15179_CR38 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-3104 – volume: 13 start-page: R47 year: 2011 ident: BFsrep15179_CR29 publication-title: Breast Cancer Res doi: 10.1186/bcr2869 – volume: 91 start-page: 1711 year: 2004 ident: BFsrep15179_CR7 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602201 – volume: 25 start-page: 2586 year: 2007 ident: BFsrep15179_CR14 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.4565 – volume: 102 start-page: 18538 year: 2005 ident: BFsrep15179_CR3 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0509182102 – volume: 32 start-page: 269 year: 2009 ident: BFsrep15179_CR43 publication-title: Am J Clin Oncol doi: 10.1097/COC.0b013e318187dd40 – volume: 126 start-page: 2635 year: 2010 ident: BFsrep15179_CR32 publication-title: Int J Cancer doi: 10.1002/ijc.24989 – volume: 299 start-page: 1057 year: 2003 ident: BFsrep15179_CR10 publication-title: Science doi: 10.1126/science.1079490 – volume: 8 start-page: 59 year: 2011 ident: BFsrep15179_CR17 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2010.56 – volume: 30 start-page: 1047 year: 2013 ident: BFsrep15179_CR30 publication-title: Clin Exp Metastasis doi: 10.1007/s10585-013-9602-9 – volume: 115 start-page: 2891 year: 2009 ident: BFsrep15179_CR40 publication-title: Cancer doi: 10.1002/cncr.24317 – volume: 6 start-page: e1000097 year: 2009 ident: BFsrep15179_CR20 publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 133 start-page: 775 year: 2008 ident: BFsrep15179_CR11 publication-title: Cell doi: 10.1016/j.cell.2008.05.009 – volume: 18 start-page: 1115 year: 2007 ident: BFsrep15179_CR28 publication-title: Oncol Rep – volume: 116 start-page: 2224 year: 2010 ident: BFsrep15179_CR26 publication-title: Cancer doi: 10.1002/cncr.24999 – volume: 27 start-page: 186 year: 2009 ident: BFsrep15179_CR19 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.18.7229 – volume: 7 start-page: e42274 year: 2012 ident: BFsrep15179_CR8 publication-title: PLoS One doi: 10.1371/journal.pone.0042274 – volume: 136 start-page: 1585 year: 2010 ident: BFsrep15179_CR4 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-010-0816-9 – volume: 107 start-page: 2866 year: 2006 ident: BFsrep15179_CR15 publication-title: Cancer doi: 10.1002/cncr.22282 – volume: 130 start-page: 67 year: 2006 ident: BFsrep15179_CR37 publication-title: Cancer Treat Res doi: 10.1007/0-387-26283-0_3 – volume: 61 start-page: 2183 year: 2012 ident: BFsrep15179_CR9 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-012-1277-6 – volume: 10 start-page: 942 year: 2004 ident: BFsrep15179_CR13 publication-title: Nat Med doi: 10.1038/nm1093 – volume: 103 start-page: 399 year: 2009 ident: BFsrep15179_CR24 publication-title: BJU Int doi: 10.1111/j.1464-410X.2008.08151.x – volume: 14 start-page: 2028 year: 2008 ident: BFsrep15179_CR45 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4554 – volume: 13 start-page: 2075 year: 2007 ident: BFsrep15179_CR23 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-2139 – volume: 68 start-page: 3907 year: 2008 ident: BFsrep15179_CR36 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6842 – volume: 108 start-page: 2957 year: 2006 ident: BFsrep15179_CR35 publication-title: Blood doi: 10.1182/blood-2006-04-018218 – volume: 313 start-page: 1960 year: 2006 ident: BFsrep15179_CR1 publication-title: Science. doi: 10.1126/science.1129139 – volume: 24 start-page: 5373 year: 2006 ident: BFsrep15179_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.9584 – volume: 137 start-page: 1270 year: 2009 ident: BFsrep15179_CR46 publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.06.053 – volume: 108 start-page: 155 year: 2013 ident: BFsrep15179_CR31 publication-title: Br J Cancer doi: 10.1038/bjc.2012.524 – volume: 18 start-page: 3022 year: 2012 ident: BFsrep15179_CR5 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-3216 |
SSID | ssj0000529419 |
Score | 2.6370158 |
SecondaryResourceType | review_article |
Snippet | The prognostic value of FoxP3
+
regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3
+... The prognostic value of FoxP3(+) regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3(+)... The prognostic value of FoxP3+ regulatory T cells (Tregs) in cancer remains controversial. We did a meta-analysis to assess the prognostic effect of FoxP3+... |
SourceID | pubmedcentral proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 15179 |
SubjectTerms | 692/499 692/53 Biomarkers, Tumor - metabolism Breast cancer Cancer Esophageal cancer Esophagus Female Forkhead Transcription Factors - immunology Foxp3 protein Head and neck Humanities and Social Sciences Humans Immunoregulation Kidneys Lymphocytes T Male Meta-analysis Metastases multidisciplinary Neoplasms - immunology Neoplasms - mortality Neoplasms - pathology Prevalence Prognosis Reproducibility of Results Risk Assessment - methods Science Sensitivity and Specificity Solid tumors Survival Survival Rate T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - pathology Tumors |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fT9wwDLbYoUl7QRtsowOmwPYwaYrojzRt9oI2BEKThk4TSLxVSZpsJ0F76_Ue-O9x2rTsAPEcS7Vix_5ip58BPvNQKMcqTuPSKspMaKlAWEBFHGthRGZZZ-lf5_zskv28Sq98wW3hn1UOMbEL1GWtXY38MMKLAV7XWM6P5v-omxrluqt-hMYLWMcQnKcTWP9xcj79PVZZXB-LRWKgFEryQ0w888jxUq0mokfo8vEjyQed0i4Bnb6GDY8cyffe1G9gzVSb8LKfJXm7Bc20qd2jOVwljsHbkNqSdnlTNxSdaHbd0eNWfwimm2nylTT9DPq6uSUXxFXvF2RWEe18oFl8I5LcUzyT_vcWIquS3JhWUumJTN7C5enJxfEZ9QMVqGZJ3lJhjSqtlankXHDLZB5ZEUodhQJjjWRoLs1MwlOFOExlWiTSOP4zgTiJK4SC72BS1ZXZBiJjqcs0R_yD97nQaKES3OlYmVTImIsogC_D7hbas427oRfXRdf1TvJiNEQAB6PovKfYeEpodzBR4U_Zorj3iQD2x2U8H27bZGXqJcpkCFJctzUP4H1v0fErCAa5Y6QPIFux9SjguLdXV6rZ346Dm_GQsSwO4NPgFf-p9VD5D88rvwOvEIZ1hLAR24VJ2yzNHkKdVn30_nwHSMIC0w priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals (WRLC) dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ1JS8UwEMcHFwQv4m7diMtBkGCXNG28yUMRQfGg4K0keYk-0Fb6-g5-eyfd9KkHz5nSkEky_zTT3wAcc18oRxWn4dAqyoxvqUBZQEUYamFEYlnt6ds7fv3Ibp7ipxYWPW7TKhukZb1Nd9lhZxgv3gOHk5qFeUdsd5j8AR_0n1PchRULRMcOitKvJ6Yjzi8Z-Tsb8seVaB1prpZhqZWI5KLp1ArMmHwVFpqikR9rUN6XhcuOw1biUN2GFJZUk7eipDhbRq81Bzd_JhhX7qNTUjbF5ovygzwQ95l-TEY50c7Z5ficSPLFcibNfyxE5kPyZipJZUssWYfHq8uHwTVtKydQzaK0osIaNbRWxpJzwS2TaWCFL3XgC9xUJEO_aGYiHisUXCrRIpLGgc4ECiKuUPNtwFxe5GYLiAylHsYpCh08uPlGCxXhSIfKxEKGXAQenHSjm-kWK-6qW7xm9fV2lGa9Izw47E3fG5bGX0a7nYuydjmNswBPhXhWZyn34KBvxoXghk3mppigTYJqxF2rph5sNh7t34Kqjzv0vAfJlK97AwfZnm7JRy81bJtxn7Ek9OComxXfuvWz89v_stqBRZRdNQA2YLswV5UTs4fSplL79aT-BNNm_DQ priority: 102 providerName: Springer Nature |
Title | Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis |
URI | https://link.springer.com/article/10.1038/srep15179 https://www.ncbi.nlm.nih.gov/pubmed/26462617 https://www.proquest.com/docview/1899788486 https://www.proquest.com/docview/1722420368 https://pubmed.ncbi.nlm.nih.gov/PMC4604472 |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9swED_6YLAvY--564L2-DAYWv2QZWswRhZaSqAlbA3km5EUaQukdus4sPz3O_m1pu2nfTJYZ1u-O_l-J8m_A_jAfaEcqzgN51ZRZnxLBcICKsJQCyMSy2pLn53z0ykbz-LZDnQ1NlsFru5N7Vw9qWm5_PznevMNB_zX5pfx9AhjyVXgqKZ2YR8DEnfOfdai_IbiOxQsEB2v0M0rHBcwZ9zRkm8Hpjto8-6myVsrp3VAOnkMj1okSYaN6Z_AjsmfwoOmtuTmGZSTsnCb6LCVOEZvQwpLqvVlUVJ8zcWypsvNfxEMP5PoEymbmvRFuSEXxM3mr8giJ9r5RLn6QiT5R_lMmt9diMzn5NJUksqW2OQ5TE-OL0antC2wQDWL0ooKa9TcWhlLzgW3TKaBFb7UgS_w2yMZmk8zE_FYIS5TiRaRNI4PTSBu4gqh4QvYy4vcvAIiQ6nncYp6xPzON1qoCJUeKhMLGXIRePCx026mW_ZxVwRjmdWr4FGa9Tbx4F0vetVQbtwndNiZKOucJgswecSUnqXcg7d9M44XpzaZm2KNMgmCFrf6mnrwsrFo_5TOFTxItmzdCzgu7u2WfPG75uRm3GcsCT1433nFjW7d7vzBf9__NTxExFZzxwbsEPaqcm3eICqq1AB2k1kygP3hcPxzjMfvx-eTH3h2xEeDeqZhUI-Kv23pFog |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Za9wwEB5CQmlfStLTbdqqFxSKiA9Ztgql9EjYNMmylA3kzZFkOVlI7I3XS9k_ld_Yka90k9K3PGvAwxyaTx7pG4B33BXKsopTP80UZcbNqEBYQIXva2FElLHa0wdDPjhkP4_CoxW47N7C2GuV3Z5Yb9Rpoe0_8i0PDwZ4XGMx_zK9oHZqlO2udiM0mrDYM4vfeGSbfd79gf597_s72-PvA9pOFaCaBXFFRWZUmmUylJwLnjEZe5lwpfZcgQknGeqsmQl4qBCMqEiLQBpLAiYQLHAlLNEBbvlrCDMEZtHat-3h6Ff_V8f2zZgnOgqjIN7CQjf1LA_WcuG7gWZvXsq81pmtC97OOtxvkSr52oTWBqyY_AHcaWZXLh5COSoLe0kPV4llDDekyEg1Py9KikE7OavpePMTguVtFHwkZTPzvigXZExst2BGJjnRNubK2SciyRWlNGme0xCZp-TcVJLKljjlERzeiqkfw2pe5OYpEOlLnYYx4i08P7pGCxWgpX1lQiF9LjwHPnTWTXTLbm6HbJwldZc9iJPeEQ686UWnDaXHv4Q2OxclbVbPkqsYdOB1v4z5aM0mc1PMUSZCUGS7u7EDTxqP9l9B8MktA74D0ZKvewHL9b28kk9Oa85vxl3GIt-Bt11U_KXWdeWf_V_5V3B3MD7YT_Z3h3vP4R5CwJqM1mObsFqVc_MCYValXraxTeD4ttPpD7KTQDI |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1taxQxEB7KFcUvxfeuVo1vIEi4fclmN4Uianu0Vo9DWui3bTab1IN299zbQ-6v-euc7Fu9VvzWzwlsNjOTeSYzeQbgDXdFalnFqZ-ZlDLtGioQFlDh-0poERlWS_rbmO8fsy8n4cka_O7ewtiyyu5MrA_qrFD2jnzoYWCA4RqL-dC0ZRGT3dGH2U9qO0jZTGvXTqNRkUO9_IXh23znYBdl_db3R3tHn_dp22GAKhbEFRVGp5kxMpScC26YjD0jXKk8V6DxSYbrV0wHPEwRmKSREoHUlhBMIHDgqbCkB3j8r0f4Q_EA1j_tjSff-xsem0NjnujojIJ4iE5v5llOrFUneA3ZXi_QvJKlrZ3f6C5stKiVfGzU7B6s6fw-3Gr6WC4fQDkpC1uwh6PEsodrUhhSLS6KkqICT89rat78jKCrmwTvSanPbNOwolySI2IzB3MyzYmy-lfOt4kkl_TSpHlaQ2SekQtdSSpbEpWHcHwjW_0IBnmR600g0pcqC2PEXhhLulqJNMCd9lMdCulz4TnwrtvdRLVM57bhxnlSZ9yDOOkF4cCrfuqsoff416StTkRJa-Hz5FIfHXjZD6Nt2m2TuS4WOCdCgGQzvbEDjxuJ9l9BIMotG74D0Yqs-wmW93t1JJ_-qPm_GXcZi3wHXnda8deyri7-yf8X_wJuoxklXw_Gh0_hDqLBmpfWY1swqMqFfoaIq0qft6pN4PSmrekPG5pEXg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+tumor-infiltrating+FoxP3%2B+regulatory+T+cells+in+cancers%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Scientific+reports&rft.au=Shang%2C+Bin&rft.au=Liu%2C+Yao&rft.au=Jiang%2C+Shu-juan&rft.au=Liu%2C+Yi&rft.date=2015-10-14&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=5&rft_id=info:doi/10.1038%2Fsrep15179&rft_id=info%3Apmid%2F26462617&rft.externalDocID=PMC4604472 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |